Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin for COVID-19
NCT04373824Unknown
- Sponsor
- Max Healthcare
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Max Healthcare. Primary endpoint: Effect of Ivermectin on eradication of virus at 3 months. Status: unknown.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04373824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04373824.